Evidence map›Paper›PMID 21838782›Full record

ArticleJournal of neurochemistry2011

The fatty acid oxidation product 15-A3t-isoprostane is a potent inhibitor of NFκB transcription and macrophage transformation.

Joshua D Brooks, Erik S Musiek, Tyler R Koestner, Jeannette N Stankowski, Jocelyn R Howard, Enrico M Brunoldi, Alessio Porta, Giuseppe Zanoni, Giovanni Vidari, Jason D Morrow and 2 more

Abstract readComparative Study
In one paragraph

Article in Journal of neurochemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. The Link Between 15-FFrontiers in veterinary science · 2022
    Article
  3. Isoprostanes in Veterinary Medicine: Beyond a Biomarker.Antioxidants (Basel, Switzerland) · 2021
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Joshua D BrooksDivision of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-8548, USA.
Erik S Musiek
Tyler R Koestner
Jeannette N Stankowski
Jocelyn R Howard
Enrico M Brunoldi
Alessio Porta
Giuseppe Zanoni
Giovanni Vidari
Jason D Morrow
Ginger L Milne
BethAnn McLaughlin
Vanderbilt University Medical Center · USJohn F. Kennedy Center for the Performing Arts · USUniversity of Pavia · IT

Funding

THREE-TIERED PREVENTION MODEL TO BETTER SERVE ALL STUDENP30HD015052 · NICHD · VANDERBILT UNIVERSITY · PI DYKENS, ELISABETH MAY · 1985 to 2014
$18.6M
THE ROLE OF ENDOCANNABINOIDS AND THEIR RECEPTORS IN COLORECTAL CANCERP01CA077839 · NCI · VANDERBILT UNIVERSITY · PI DUBOIS, RAYMOND N. · 1999 to 2016
$17.8M
THE PHARMACOLOGY OF INHIBITORS OF HEME PROTEIN-CATALYZED LIPID PEROXIDATIONP50GM015431 · NIGMS · VANDERBILT UNIVERSITY · PI CAPRIOLI, RICHARD M · 1985 to 2010
$15.0M
Therapeutic Modulation of Endothelial Cell TetrahydrobiopterinP01GM015431 · NIGMS · VANDERBILT UNIVERSITY · PI MARNETT, LAWRENCE J. · 2011 to 2015
$9.5M
Training in Fundamental NeuroscienceT32MH064913 · NIMH · VANDERBILT UNIVERSITY · PI IHRIE, REBECCA A, WINDER, DANNY G. · 2001 to 2022
$7.6M
Program in NeurogenomicsT32MH065215 · NIMH · VANDERBILT UNIVERSITY · PI ROGER J COLBRAN · 2002 to 2026
$6.4M
BIOCHEMISTRY AND PHARMACOLOGY OF D2/E2-ISOPROSTANESR01DK048831 · NIDDK · VANDERBILT UNIVERSITY · PI YIN, HUIYONG · 1995 to 2008
$2.2M
Cellular Mechanisms of Preconditioning NeuroprotectionR01NS050396 · NINDS · VANDERBILT UNIVERSITY · PI MCLAUGHLIN, BETHANN M · 2005 to 2009
$1.7M
CELLULAR AND MOLECULAR NEUROSCIENCE TRAININGT32MH019732 · NIMH · VANDERBILT UNIVERSITY · PI BLAKELY, RANDY D · 1992 to 2001
$284k
NCI NIH HHS CA77839NCI NIH HHS P01 CA077839NICHD NIH HHS P30 HD015052NICHD NIH HHS P30HD15052NIDDK NIH HHS DK48831NIDDK NIH HHS R01 DK048831NIGMS NIH HHS GM15431NIGMS NIH HHS P01 GM015431NIGMS NIH HHS P50 GM015431NIMH NIH HHS T32 MH019732NIMH NIH HHS T32 MH064913NIMH NIH HHS T32 MH065215NINDS NIH HHS NS050396NINDS NIH HHS R01 NS050396
6 · The paper itself

Abstract

Fatty acids such as eicosapentaenoic acid (EPA) have been shown to be beneficial for neurological function and human health. It is widely thought that oxidation products of EPA are responsible for biological activity, although the specific EPA peroxidation product(s) which exert these responses have not yet been identified. In this work we provide the first evidence that the synthesized representative cyclopentenone IsoP, 15-A(3t)-IsoP, serves as a potent inhibitor of lipopolysaccharide-stimulated macrophage activation. The anti-inflammatory activities of 15-A(3t)-IsoP were observed in response not only to lipopolysaccharide, but also to tumor necrosis factor alpha and IL-1b stimulation. Subsequently, this response blocked the ability of these compounds to stimulate nuclear factor kappa b (NFκB) activation and production of proinflammatory cytokines. The bioactivity of 15-A(3t)-IsoP was shown to be dependent upon an unsaturated carbonyl residue which transiently adducts to free thiols. Site directed mutagenesis of the redox sensitive C179 site of the Ikappa kinase beta subunit, blocked the biological activity of 15-A(3t)-IsoP and NFκB activation. The vasoprotective potential of 15-A(3t)-IsoP was underscored by the ability of this compound to block oxidized lipid accumulation, a critical step in foam cell transformation and atherosclerotic plaque formation. Taken together, these are the first data identifying the biological activity of a specific product of EPA peroxidation, which is formed in abundance in vivo. The clear mechanism linking 15-A(3t)-IsoP to redox control of NFκB transcription, and the compound's ability to block foam cell transformation suggest that 15-A(3t)-IsoP provides a unique and potent tool to provide vaso- and cytoprotection under conditions of oxidative stress.

Indexed as

AnimalsCell LineFatty AcidsIsoprostanesMacrophage ActivationMacrophagesMiceNF-kappa BOxidation-ReductionOxidative StressTranscription, GeneticFatty AcidsIsoprostanesNF-kappa B

Identifiers

PMID21838782
PMCPMC3640263
OpenAlexW1720612225

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.